Proof of concept for the clinical utility of a convection enhanced delivery platform for immuno-oncology drugs against brain tumors
Year: 2019
Type: article
Abstract: Here we present a post-hoc analysis of the long-term follow-up data for the Phase IIB study NCT00431561 regarding the clinical activity of the TGFbeta2-specific RNA therapeutic OT101/Trabedersen in recurrent/refractory WHO Grade 3 anaplastic astrocytoma (R/R AA) patients.OT101 was administered intratumorally by continuous infusion via CEDOT for 5 consecutive months to 27 recurrent/refractory WHO Grade 3 anaplastic astrocytoma (R/R AA) patients in two dose cohorts (2.5 mg/cycle and 19.8 mg/cycle).14 of the 27 patients (51.9%) had a sustained partial response (PR) or complete response (CR).The median overall survival (OS) time of 1136 days was significantly better than the 590 days median OS (Log Rank χ 2 =6.5, P-value=0.011) of the temozolomide (TMZ)-treated control patient population (N=11).
Source: Cancer Reports and Reviews
DOI: 10.15761/crr.1000197
Authors: Fatih M. Uckun, Sanjive Qazi, Vuong N. Trieu
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3033303000